Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology
+$0.29 today
- Market cap
- $1.52B
- Beta
- 0.20
- P/E (TTM)
- 27.8
- EPS (TTM)
- $0.62
Volume 2.07M
Average 3.08M
Returns on capital
Sarepta Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-62.5%
avg -66.7%
ROIC
-29.0%
avg -31.8%
ROA
-21.3%
avg -26.8%
Analysis
ROA is currently the strongest return metric at -21.3% versus its period average of -26.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Michael E. Severino | Chief Executive Officer & Director | USD 1.84M | 60 | — | — |
Douglas S. Ingram | Advisor | USD 1.84M | 63 | 440.31K | 0.42% |
Louise R. Rodino-Klapac | President of Research & Development and Technical Operations | USD 1.03M | 48 | — | — |
Ian Michael Estepan | President & Chief Operating Officer | USD 1.02M | 50 | 177.18K | 0.17% |
Cristin L. Rothfuss | Executive Vice President, General Counsel & Company Secretary | USD 806.78K | 58 | — | — |
Ryan H. Wong | Executive Vice President & Chief Financial Officer | USD 633.9K | 47 | — | — |
Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer | — | — | — | — |
Alison Nasisi | Executive Vice President & Chief People Officer | — | — | — | — |
Rachael Potter | Chief Scientific Officer | — | — | — | — |
Tamara Thornton | Director of Finance, Treasury & Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 4, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$417,409.75
Net Transaction Value
−$417,409.75
Net selling
Most Active
Mayo Stephen
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 12, 26Mar 12, 2026 | Mayo Stephen Direct | Sell | $123.2K$123,207.78 |
| Dec 16, 25Dec 16, 2025 | Estepan Ian Michael Direct | Sell | $294.2K$294,201.97 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $417,409.75 over the last 12 months. That adds up to net selling of $417,409.75. Mayo Stephen was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +33.1% | -12.2% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.1% over three years. Forward estimates point to Revenue at -12.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Sarepta Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about SRPT's management, answered from reported figures.
Who manages SRPT?
Sarepta Therapeutics, Inc. (SRPT) lists 10 active executives. The top listed executive is Diane L. Berry, Executive Vice President and Chief of Global Policy & Advocacy Officer.
Are SRPT insiders buying or selling?
Recent insider activity shows net buying of $37.97M.
Continue the stock analysis
Jump to another research area for this company.